News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
729,486 Results
Type
Article (43216)
Company Profile (464)
Press Release (685796)
Multimedia
Podcasts (108)
Webinars (20)
Section
Business (209123)
Career Advice (2032)
Deals (36086)
Drug Delivery (109)
Drug Development (83825)
Employer Resources (174)
FDA (16593)
Job Trends (15166)
News (353693)
Policy (33236)
Tag
Academia (2648)
Accelerated approval (18)
Adcomms (28)
Allergies (119)
Alliances (51109)
ALS (142)
Alzheimer's disease (1615)
Antibody-drug conjugate (ADC) (237)
Approvals (16670)
Artificial intelligence (421)
Autoimmune disease (88)
Automation (29)
Bankruptcy (373)
Best Places to Work (11840)
BIOSECURE Act (20)
Biosimilars (152)
Biotechnology (331)
Bladder cancer (135)
Brain cancer (48)
Breast cancer (496)
Cancer (3917)
Cardiovascular disease (326)
Career advice (1713)
Career pathing (34)
CAR-T (236)
CDC (44)
Cell therapy (638)
Cervical cancer (31)
Clinical research (70032)
Collaboration (1372)
Company closure (4)
Compensation (931)
Complete response letters (51)
COVID-19 (2739)
CRISPR (81)
C-suite (590)
Cystic fibrosis (137)
Data (4688)
Decentralized trials (2)
Denatured (35)
Depression (104)
Diabetes (426)
Diagnostics (6599)
Digital health (34)
Diversity (11)
Diversity, equity & inclusion (45)
Drug discovery (197)
Drug pricing (167)
Drug shortages (29)
Duchenne muscular dystrophy (203)
Earnings (90150)
Editorial (49)
Employer branding (21)
Employer resources (152)
Events (119053)
Executive appointments (956)
FDA (19061)
Fibrodysplasia Ossificans Progressiva (4)
Friedreich's ataxia (6)
Frontotemporal dementia (16)
Funding (1243)
Gene editing (171)
Generative AI (32)
Gene therapy (523)
GLP-1 (912)
Government (4699)
Grass and pollen (5)
Guidances (363)
Healthcare (19188)
HIV (44)
Huntington's disease (38)
IgA nephropathy (63)
Immunology and inflammation (224)
Immuno-oncology (19)
Indications (58)
Infectious disease (2966)
Inflammatory bowel disease (181)
Inflation Reduction Act (16)
Influenza (95)
Intellectual property (192)
Interviews (315)
IPO (16899)
IRA (51)
Job creations (3710)
Job search strategy (1439)
Kidney cancer (15)
Labor market (73)
Layoffs (567)
Leadership (29)
Legal (8014)
Liver cancer (87)
Longevity (11)
Lung cancer (564)
Lymphoma (265)
Machine learning (30)
Management (59)
Manufacturing (606)
MASH (139)
Medical device (13774)
Medtech (13797)
Mergers & acquisitions (20073)
Metabolic disorders (1081)
Multiple sclerosis (134)
NASH (19)
Neurodegenerative disease (217)
Neuropsychiatric disorders (58)
Neuroscience (2625)
NextGen: Class of 2025 (6758)
Non-profit (4563)
Now hiring (59)
Obesity (515)
Opinion (261)
Ovarian cancer (137)
Pain (157)
Pancreatic cancer (171)
Parkinson's disease (236)
Partnered (28)
Patents (408)
Patient recruitment (321)
Peanut (53)
People (59664)
Pharmaceutical (86)
Pharmacy benefit managers (25)
Phase I (21992)
Phase II (30877)
Phase III (22853)
Pipeline (2744)
Policy (260)
Postmarket research (2602)
Preclinical (9444)
Press Release (67)
Prostate cancer (198)
Psychedelics (50)
Radiopharmaceuticals (275)
Rare diseases (650)
Real estate (6045)
Recruiting (70)
Regulatory (23990)
Reports (51)
Research institute (2448)
Resumes & cover letters (353)
Rett syndrome (15)
RNA editing (15)
RSV (67)
Schizophrenia (134)
Series A (207)
Series B (157)
Service/supplier (11)
Sickle cell disease (80)
Special edition (25)
Spinal muscular atrophy (154)
Sponsored (36)
Startups (3789)
State (2)
Stomach cancer (15)
Supply chain (94)
Tariffs (80)
The Weekly (71)
Vaccines (932)
Venture capital (65)
Weight loss (340)
Women's health (57)
Worklife (18)
Date
Today (135)
Last 7 days (666)
Last 30 days (2710)
Last 365 days (31335)
2025 (25769)
2024 (36300)
2023 (41015)
2022 (52277)
2021 (56763)
2020 (54920)
2019 (47416)
2018 (35696)
2017 (33023)
2016 (32346)
2015 (38396)
2014 (32185)
2013 (27109)
2012 (29220)
2011 (29863)
2010 (27993)
Location
Africa (746)
Alabama (77)
Alaska (7)
Arizona (278)
Arkansas (14)
Asia (40136)
Australia (6671)
California (9453)
Canada (2858)
China (887)
Colorado (396)
Connecticut (416)
Delaware (264)
Europe (87962)
Florida (1393)
Georgia (304)
Hawaii (2)
Idaho (60)
Illinois (737)
India (48)
Indiana (454)
Iowa (20)
Japan (322)
Kansas (122)
Kentucky (36)
Louisiana (19)
Maine (68)
Maryland (1235)
Massachusetts (6998)
Michigan (284)
Minnesota (546)
Mississippi (4)
Missouri (111)
Montana (31)
Nebraska (25)
Nevada (103)
New Hampshire (77)
New Jersey (2608)
New Mexico (30)
New York (2548)
North Carolina (1328)
North Dakota (9)
Northern California (4373)
Ohio (286)
Oklahoma (20)
Oregon (41)
Pennsylvania (1978)
Puerto Rico (19)
Rhode Island (44)
South America (1113)
South Carolina (48)
South Dakota (1)
Southern California (3626)
Tennessee (148)
Texas (1460)
United States (34380)
Utah (277)
Virginia (226)
Washington D.C. (78)
Washington State (800)
West Virginia (4)
Wisconsin (82)
Wyoming (1)
729,486 Results for "carisma therapeutics inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Layoffs
Carisma Lays Off Most of Staff, Eyes Sale of Assets and Company
Cell therapy and oncology–focused Carisma Therapeutics started layoffs late last year. Now the company plans to wind down fully.
April 1, 2025
·
1 min read
·
Dan Samorodnitsky
Layoffs
Carisma Therapeutics to Cut 34% of Staff, Reprioritize Pipeline
Carisma’s second workforce reduction this year likely leaves the company with 44 full-time employees as turns its focus to developing therapies for fibrosis, oncology and autoimmune diseases.
December 10, 2024
·
2 min read
·
Angela Gabriel
Press Releases
Carisma Therapeutics and OrthoCellix Enter into Definitive Merger Agreement to Create Company Focused on Regenerative Cell Therapies for Orthopedic Diseases
June 23, 2025
·
19 min read
Pharm Country
Carisma Therapeutics to Participate in the Jefferies Global Healthcare Conference
Carisma Therapeutics Inc. today announced that Steven Kelly , President and Chief Executive Officer, will participate in a fireside chat at the Jefferies Global Healthcare Conference.
May 30, 2024
·
1 min read
Business
Carisma Therapeutics Announces Changes to its Board of Directors - July 1, 2024
Carisma Therapeutics Inc. today announced the appointment of Marella Thorell and David Scadden, M.D., to the Company’s Board of Directors, effective June 30, 2024.
July 1, 2024
·
4 min read
Pharm Country
Carisma Therapeutics to Participate in the Stifel 2024 Cell Therapy Forum
Carisma Therapeutics Inc. today announced that Steven Kelly , President and Chief Executive Officer, will participate in a fireside chat at the Stifel 2024 Cell Therapy Forum on Tuesday, July 9th at 9:10 am ET.
June 25, 2024
·
1 min read
Business
Carisma Therapeutics Announces Changes to its Board of Directors
Carisma Therapeutics Inc. today announced the appointment of John Hohneker, M.D. to the Board of Directors.
April 1, 2024
·
3 min read
Business
Carisma Therapeutics Announces Nomination of First In Vivo CAR-M Development Candidate for Hepatocellular Carcinoma Under Collaboration with Moderna
Carisma Therapeutics Inc. (Nasdaq: CARM) (“Carisma” or the “Company”), a clinical stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, today announced the nomination of the first development candidate (“Development Candidate”), under its collaboration with Moderna, Inc.
June 27, 2024
·
6 min read
Business
Carisma Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights
Carisma Therapeutics Inc. (Nasdaq: CARM) (“Carisma” or the “Company”), a clinical-stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, today reported financial results for the quarter ended March 31, 2024, and highlighted recent business updates.
May 9, 2024
·
14 min read
Pharm Country
Carisma Therapeutics to Present at Upcoming April 2024 Conferences
Carisma Therapeutics Inc., a clinical-stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, announced that it will present at the following upcoming conferences.
April 3, 2024
·
1 min read
1 of 72,949
Next
